Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma
NCT07684950Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in mantle cell lymphoma (MCL), sponsored by Henan Cancer Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07684950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684950.